Chlorine Dioxide, Raw Camel Milk: The FDA No Longer Warns Against These and Other Ineffective Autism Treatments

Why It Matters

Eliminating the FDA warning may legitimize hazardous, unproven autism treatments and erode public trust in health regulators.

Key Takeaways

• FDA withdrew autism treatment warning page in 2025
• Kennedy reshapes HHS autism panel with alternative‑medicine advocates
• Chlorine dioxide remains unregulated, despite safety concerns
• Past chelation and hyperbaric therapies linked to child deaths
• Advocacy groups warn against legitimizing unproven autism cures

Pulse Analysis

In late 2025 the Food and Drug Administration quietly removed a consumer‑facing webpage that listed chlorine dioxide, raw camel milk, chelation and hyperbaric oxygen as dangerous, ineffective autism treatments. The agency cited a routine cleanup of outdated content, noting the page had not been updated since 2019. While the page remains accessible via the Internet Archive, its disappearance eliminates an official federal warning that many parents relied on when evaluating fringe remedies. The move has sparked concern that the government is retreating from its role as a gatekeeper of health misinformation.

The timing coincides with the appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services, a figure known for championing unproven therapies and questioning vaccine safety. Kennedy has reshaped the inter‑agency autism coordinating committee, replacing seasoned researchers with advocates of chelation, hyperbaric chambers, and even experimental drugs like suramin. By aligning federal advisory bodies with the alternative‑medicine community, the administration signals a potential policy shift that could legitimize treatments lacking rigorous clinical evidence. This realignment also reflects broader political currents that prioritize deregulation of non‑patentable health products.

Public‑health experts warn that the loss of an explicit FDA warning may embolden marketers and vulnerable families. Historical cases—such as the 2005 Pennsylvania chelation death and the 2026 Michigan hyperbaric chamber fire—illustrate the lethal stakes of untested interventions. Advocacy groups, including the Autistic Self‑Advocacy Network, argue that the federal retreat undermines evidence‑based care and could divert resources from therapies that have demonstrably improved outcomes for 70‑75 % of autistic children. Maintaining clear, science‑based guidance remains essential to protect patients and preserve trust in regulatory institutions.